NCT00758927View on ClinicalTrials.gov

The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

July 31, 2010

Conditions
Diabetes Mellitus, Type 2HypercholesterolemiaHypertriglyceridemia
Interventions
DRUG

Omega-3 acid 4 grams per day

OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy

DRUG

Placebo control

Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm

Trial Locations (3)

602-715

RECRUITING

Dong-A University Medical Center, Busan

614-735

RECRUITING

Paik Diabetes Center, Busan

Unknown

RECRUITING

Endocrinology and Metabolism, Maryknoll General Hospital, Busan

Sponsors
All Listed Sponsors
lead

Inje University

OTHER

collaborator

Kuhnil Pharmaceutical Co., Ltd.

INDUSTRY

NCT00758927 - The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter